Seraseq NGS Technology
Developing and optimizing next-generation sequencing (NGS) assays is a difficult task. Successful assays require accuracy throughout the entire process, from sample DNA purification and quantitation, to library construction and template preparation, through bioinformatics parameters and variant annotation.
Flexible, highly-multiplexed NGS products
SeraCare’s Seraseq NGS technology offers scalability, flexibility, and commutability, which is responsive to the needs of in vitro diagnostics (IVD) manufacturers and clinical laboratories. By using engineered cell lines and biosynthetic DNA targets, SeraCare can produce highly multiplexed reference standards for the demands of highly multiplexed assays that current NGS platforms provide.
Biosynthetic DNA and engineered cell lines
Production of biosynthetic DNA with sequences that occur rarely in patient samples solves the problem of sourcing these rare materials in limited supply. In addition, the use of biosynthetic DNA and engineered cell lines creates the ability to adjust individual allele frequency or fetal fraction percentages to a given commonly accepted limit of detection, or the ability to customize a set of allele frequencies or fetal fraction percentages to user requirements.
Related Seraseq products
- Prenatal Diagnostics (NIPT)
- Inherited Disease
- Infectious Disease
- NGS Reference Materials (RUO)
Full process reference materials provide maximum usability
The use of stable circulating cell-free DNA in synthetic plasma-like material and formalin-fixed, paraffin-embedded (FFPE) cell lines enables Seraseq products to serve as full-process reference materials, monitoring the entire workflow. These reference standards can be handled in an identical fashion as a patient sample in procedures including:
- Nucleic acid extraction
- NGS library construction
- Template preparation
- Data analysis